England is set to pioneer a pioneering seven-minute cancer therapy in a historic leap in oncology. This surprising breakthrough has the potential to revolutionize cancer therapy by dramatically reducing treatment time while increasing effectiveness.
The England programme, which has the potential to become a world benchmark, has the potential to transform cancer treatment methods.
jump to
- Faster, better and stronger: England’s initiative for a seven-minute hit against cancer
- Atezolizumab: an injection that will help many
Faster, better and stronger: England’s initiative for a seven-minute hit against cancer
Credit: Pixaby
The novel injection method can reduce treatment time by up to 75%. The immunotherapy atezolizumab, commonly known as Tecentriq, is administered intravenously, directly into patients’ veins via a drip.
However, once approved by the Medicines and Healthcare Products Regulatory Agency (MHRA), hundreds of patients could switch to receiving the drug by injection.
This takes about seven minutes, as opposed to 30 to 60 minutes for an intravenous transfusion.
The treatment is administered to patients with a variety of malignancies, including those of the lung, breast, liver and bladder. The drug, known as a “checkpoint inhibitor,” works by helping the immune system locate and kill cancer cells.
NHS England stated that the majority of the approximately 3,600 patients who start atezolizumab therapy each year will switch to injectables.
However, people taking intravenous chemotherapy with atezolizumab can continue to receive the transfusion.
Credit: Canva
The “world’s first treatment” will allow “hundreds of patients to spend less time in hospital and free up valuable time in NHS chemotherapy units,” according to NHS England’s national director of cancer, Professor Peter Johnson.
“It is critical to keep cancer patients as comfortable as possible, so the introduction of faster subcutaneous injections will make a significant difference.
Atezolizumab: an injection that will help many
This immunotherapy drug, made by Roche subsidiary Genentech, helps a patient’s immune system find and kill cancer cells. The therapy is now given by transfusion to NHS patients suffering from lung, breast, liver and bladder cancer.
According to studies, most cancer patients prefer to receive treatment subcutaneously (by injection or infusion just under the skin) because it causes less pain and discomfort, is easier to administer, and takes less time than an IV infusion. .
Credit: Canva
Thousands of cancer patients in England have benefited from the intravenous form of atezolizumab, which has been shown to dramatically reduce the chances of cancer recurrence.
After surgery and chemotherapy, clinical trials have shown that atezolizumab can reduce the risk of cancer recurrence or mortality by 34% in people with early-stage non-small cell lung cancer.
By making cancer cells more obvious to the immune system, the new treatment works by inhibiting a protein that prevents the immune system from attacking cancer cells. On Tuesday, it was also revealed that the addition of three recognized organizations had strengthened the UK’s ability to certify medical devices.
The change aims to nearly double existing capacity, providing patients with more effective products.
what do you think about it? Let us know in the comments.
For more trending stories, follow us on Telegram.
Categories: Trending
Source: vtt.edu.vn